Irini Sereti1, Roy M Gulick2, Sonya Krishnan1, Stephen A Migueles3, Adrian Palfreeman4, Veronique Touzeau-Römer5, Waldo H Belloso6, Sean Emery7, Matthew G Law8. 1. HIV Pathogenesis Section, NIAID/NIH, Bethesda, MD. 2. Infectious Diseases, Weill Cornell Medicine, Weill Cornell Medical College, Cornell University, New York, NY. 3. HIV-Specific Immunity Section, NIAID/NIH, Bethesda, MD. 4. Department of Genitourinary Medicine, Leicester Royal Infirmary, Leicester, United Kingdom. 5. Department of Immunodermatology and Infectious Skin Diseases, University Vienna General Hospital, Vienna, Austria. 6. CICAL and Infectious Diseases Section, Internal Medicine Service, Hospital Italiano de Buenos Aires Argentina, Buenos Aires, Argentina. 7. Faculty of Medicine, University of New South Wales, Sydney, Australia. 8. Faculty of Medicine, Kirby Institute, University of New South Wales, Sydney, Australia.
Abstract
BACKGROUND: The benefit of immediate antiretroviral therapy (ART) at CD4 >500 cells/μL was established in the Strategic Timing of Antiretroviral Treatment (START) study. The benefits and risks of immediate ART in participants with low pretreatment viremia, including virologic suppressors, were further assessed. SETTING: Randomized prospective international study. METHODS:START participants with enrollment viremia <3000 c/mL were included. We compared clinical outcomes (grade 4 adverse events, hospitalizations, or death), plasma viremia, CD4 counts, and changes in biomarkers in immediate versus deferred ART groups. RESULTS:Participants (N = 1134 including 93 with viremia ≤50 c/mL) had a median age of 37 years, 40% were women, and median CD4 was 713 cells/µL. Ninety-seven percent in the immediate and 29% in the deferred arm initiated ART at a median of 6 and 699 days, respectively. Clinical outcomes were experienced in 64 versus 61 patients in immediate and deferred arms (hazard ratio 1.10, 95% confidence interval: 0.77 to 1.56). The CD4 count difference was 125 cells/µL at 12 and 235 cells/µL at 36 months higher in the immediate versus deferred groups. D-dimer and VCAM levels decreased, and C-reactive protein increased, in the immediate arm at month 8. No significant changes in CD4 counts or biomarkers were observed in persons who maintained spontaneous virologic suppression. CONCLUSIONS: START participants with low enrollment viremia experienced higher CD4 counts, greater proportion with suppressed viremia, and decreases in D-dimer levels on immediate ART despite the lack of difference in serious clinical outcomes. These data support immediate ART in people with low viremia, although equipoise remains for suppressors.
RCT Entities:
BACKGROUND: The benefit of immediate antiretroviral therapy (ART) at CD4 >500 cells/μL was established in the Strategic Timing of Antiretroviral Treatment (START) study. The benefits and risks of immediate ART in participants with low pretreatment viremia, including virologic suppressors, were further assessed. SETTING: Randomized prospective international study. METHODS: START participants with enrollment viremia <3000 c/mL were included. We compared clinical outcomes (grade 4 adverse events, hospitalizations, or death), plasma viremia, CD4 counts, and changes in biomarkers in immediate versus deferred ART groups. RESULTS:Participants (N = 1134 including 93 with viremia ≤50 c/mL) had a median age of 37 years, 40% were women, and median CD4 was 713 cells/µL. Ninety-seven percent in the immediate and 29% in the deferred arm initiated ART at a median of 6 and 699 days, respectively. Clinical outcomes were experienced in 64 versus 61 patients in immediate and deferred arms (hazard ratio 1.10, 95% confidence interval: 0.77 to 1.56). The CD4 count difference was 125 cells/µL at 12 and 235 cells/µL at 36 months higher in the immediate versus deferred groups. D-dimer and VCAM levels decreased, and C-reactive protein increased, in the immediate arm at month 8. No significant changes in CD4 counts or biomarkers were observed in persons who maintained spontaneous virologic suppression. CONCLUSIONS: START participants with low enrollment viremia experienced higher CD4 counts, greater proportion with suppressed viremia, and decreases in D-dimer levels on immediate ART despite the lack of difference in serious clinical outcomes. These data support immediate ART in people with low viremia, although equipoise remains for suppressors.
Authors: Trevor A Crowell; Kelly A Gebo; Joel N Blankson; P Todd Korthuis; Baligh R Yehia; Richard M Rutstein; Richard D Moore; Victoria Sharp; Ank E Nijhawan; W Christopher Mathews; Lawrence H Hanau; Roberto B Corales; Robert Beil; Charurut Somboonwit; Howard Edelstein; Sara L Allen; Stephen A Berry Journal: J Infect Dis Date: 2014-12-15 Impact factor: 5.226
Authors: Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks Journal: J Infect Dis Date: 2008-01-01 Impact factor: 5.226
Authors: Jason V Baker; Shweta Sharma; Birgit Grund; Adam Rupert; Julia A Metcalf; Mauro Schechter; Paula Munderi; Inka Aho; Sean Emery; Abdel Babiker; Andrew Phillips; Jens D Lundgren; James D Neaton; H Clifford Lane Journal: Open Forum Infect Dis Date: 2017-11-28 Impact factor: 3.835
Authors: Duncan Churchill; Laura Waters; Nadia Ahmed; Brian Angus; Marta Boffito; Mark Bower; David Dunn; Simon Edwards; Carol Emerson; Sarah Fidler; Martin Fisher; Rob Horne; Saye Khoo; Clifford Leen; Nicola Mackie; Neal Marshall; Fernando Monteiro; Mark Nelson; Chloe Orkin; Adrian Palfreeman; Sarah Pett; Andrew Phillips; Frank Post; Anton Pozniak; Iain Reeves; Caroline Sabin; Roy Trevelion; John Walsh; Ed Wilkins; Ian Williams; Alan Winston Journal: HIV Med Date: 2016-08 Impact factor: 3.180
Authors: Hiroyu Hatano; Steven A Yukl; April L Ferre; Erin H Graf; Ma Somsouk; Elizabeth Sinclair; Mohamed Abdel-Mohsen; Teri Liegler; Kara Harvill; Rebecca Hoh; Sarah Palmer; Peter Bacchetti; Peter W Hunt; Jeffrey N Martin; Joseph M McCune; Russell P Tracy; Michael P Busch; Una O'Doherty; Barbara L Shacklett; Joseph K Wong; Steven G Deeks Journal: PLoS Pathog Date: 2013-10-10 Impact factor: 6.823